NUTEK has joined the fight against cancer by actively addressing the problem of cancer tissues that remain undetected on the patient's body after surgical intervention which is the main cause of subsequent cancer recurrence, repeated operations, and aggressive treatments.

Furthermore, the resulting economic burden on hospitals, healthcare organizations insurance companies is significantly high.The current Golden Standard is the histopathology analysis which is done on the resected tumour margins.

Typically, the results are only available a few days after the surgery has been completed.

NUTEK provides a unique intraoperative solution.

It is a high-resolution hyperspectral imaging handheld device called the "Rainbow Probe" which surgeons will be able to use to scan the operation cavity on the patient’s body during surgery.

The probe guides the surgeon to the exact location of any remaining cancerous tissue for immediate removal, prior to closing.Our first application is Breast Cancer, to be followed with high-precision, minimally invasive cancer operations.We are collaborating with the Medical University of Graz (Austria) and have received a major grant from the FFG (Austrian Innovation Authority).

We established a subsidiary company in Graz (NUTEK AT GmbH) for our pre-clinical trials on human tissues (Breast cancer) and product development.

By December 2023, we plan to have a fully functional TRL 6 MVP and in September 2024 we plan to have a fully functional TRL 7 prototype.We are seeking additional investment in order to complete the development and testing process and place this life-saving device in the hands of healthcare providers as soon as possible.